

# Anne Constanze Regierer

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8357099/anne-constanze-regierer-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10  
papers

187  
citations

5  
h-index

11  
g-index

11  
ext. papers

262  
ext. citations

4.3  
avg, IF

2.55  
L-index

#	Paper	IF	Citations
10	Biomarkers of depression in cancer patients. <i>Cancer</i> , <b>2006</b> , 107, 2723-9	6.4	101
9	Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	33
8	National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	26
7	Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis. <i>Breast Care</i> , <b>2008</b> , 3, 118-123	2.4	10
6	The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. <i>Seminars in Oncology</i> , <b>2009</b> , 36, S55-68	5.5	8
5	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , <b>2021</b> , 7, e001896	5.9	4
4	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	2
3	Mammakarzinom bei älteren Patientinnen [Altersgerechte adjuvante systemische Therapie. <i>Klinikerarzt</i> , <b>2011</b> , 40, 358-361	0	
2	Systemische Therapie des Mammakarzinoms - State of the Art. <i>Klinikerarzt</i> , <b>2012</b> , 41, 146-149	0	
1	Risikostratifizierung für Therapieentscheidungen bei Rheumatoider Arthritis. <i>Aktuelle Rheumatologie</i> , <b>2021</b> , 46, 143-148	0.1	